In the first place, as anticipated above, NAPRT gene amplification is well documented in a wide spectrum of solid tumors, including, but not limited to, ovarian, prostate, and pancreatic cancer (all showing an amplification frequency between 25% and 35% of the studied cases), and this correlates with a high expression of NAPRT mRNA [69,70]. This evidence concerns the gene NAPRT and familial pancreatic carcinoma.